Recent research suggests that epigenetic alterations involving DNA methylation can be causative for neurodevelopmental, growth and metabolic disorders. Although lymphoblastoid cell lines have been an invaluable resource for the study of both genetic and epigenetic disorders, the impact of EBV transformation, cell culturing and freezing on epigenetic patterns is unknown. We compared genome-wide DNA methylation patterns of four white blood cell samples, four low-passage lymphoblastoid cell lines pre and post freezing and four high-passage lymphobastoid cell lines, using two microarray platforms: Illumina HumanMethyla-tion27 platform containing 27,578 CpG sites and Agilent Human CpG island Array containing 27,800 CpG islands. Comparison of genome-wide methylation profiles between white blood cells and lymphoblastoid cell lines demonstrated methylation alterations in lymphoblastoid cell lines occurring at random genomic locations. These changes were more profound in high-passage cells. Freezing at low-passages did not have a significant effect on DNA methylation. Methylation changes were observed in several imprinted differentially methylated regions, including DIRAS3, NNAT, H19, MEG3, NDN and MKRN3, but not in known imprinting centers. Our results suggest that lymphoblastoid cell lines should be used with caution for the identification of disease-associated DNA methylation changes or for discovery of new imprinted genes, as the methylation patterns seen in these cell lines may not always be representative of DNA methylation present in the original B-lymphocytes of the patient.
Introduction
Immortalized lymphoblastoid cell lines (LCLs) are of great practical value for human genetics, because they provide a virtually unlimited source of DNA. Many publicly available research repositories store LCLs derived from both healthy individuals and individuals with various disorders. These cell lines have been particularly useful for genetic studies despite rare cases of genomic instability [1] .They have also been successfully used for gene expression analyses in neuropsychiatric disorders [2, 3] . Given the attention focused now on discovery of epigenetic determinants in human disorders, we studied the stability of epigenetic marks in LCLs, easily accessible cell lines for such research.
DNA methylation is an important epigenetic mechanism regulating gene expression. It occurs predominantly at cytosines of CpG dinucleotides. CpGs are distributed non-randomly in the genome. For 98% of the genome, CpG sites occur at low frequency once per 80 dinucleotides. CpG islands range in size from 200 bp to several kb, comprise 1-2% of the genome, and have a five-fold higher concentration of CpGs than the rest of the genome [4] . The CpG islands commonly associated with gene promoters are usually not methylated. Important exceptions are the imprinted genes and genes on the inactive X chromosome [4] . Normally methylation of promoters containing CpG islands causes gene silencing. However, for CpG poor promoters there are conflicting reports about the effect of methylation on gene expression [5, 6] .
Aberrant DNA methylation can result in various disorders including cancer [7] and imprinting disorders [8, 9] . Whole genome based approaches such as microarrays and deep genome sequencing have presented new opportunities to identify epigenetic defects associated with human diseases. In many cases, DNA from LCLs might be considered the best available material for such experiments. However, the essential question is: normal methylation marks retained in LCLs? There are several factors that could potentially change methylation patterns in LCLs as compared to B-lymphocytes, from which they originate. These include Epstein Barr virus infection and subsequent immortalization, cell culture conditions and freezing cycles. Two types of altered methylation patterns could theoretically occur. De novo methylation of normally unmethylated sequences could occur via DNA methyltransferase activity. Alternatively, loss of methylation could occur either passively through failure of DNA Genomics 95 (2010) 73-83 methylation maintenance following DNA replication cycle, or actively by demethylating activity; however no enzyme with such activity has been identified to date. If DNA methylation changes were to occur in LCLs at specific genomic locations, this would not be a problem for epigenetic research, as the probes for these genomic regions could be excluded from the analysis. However, if methylation changes occur at random genomic locations in LCLs, this could invalidate experiments targeting the identification of candidate DNA methylation changes associated with a specific disease. This is because it would not be clear whether the altered DNA methylation pattern represents the original patient's DNA profile or whether it reflects in vitro changes that occur during cell line establishment and maintenance.
Our experiments were designed to explore the scope of epigenetic alterations occurring in LCLs and how that might impact the use of these lines for epigenetic discoveries. We compared genome-wide DNA methylation profiles from LCLs and white blood cells (WBCs) using two technologies: methylated DNA immunoprecipitation followed by Agilent CpG island array (27, 800 CpG islands) and Illumina's Infinium HumanMethylation27 BeadChip (27, 578 individual CpG dinucleotides spanning 14,495 genes). Our goal was to determine the utility of these two platforms to identify methylation changes in comparisons of methylation profiles of WBCs and LCLs. We compared four WBC samples, four low passage LCLs (LP_LCLs) and four low passage LCLs after freezing (FR_LCLs) from the same individuals and four unrelated high passage previously frozen LCLs (HP_LCLs). We used both Illumina and Agilent platforms for genomewide correlation analysis and analysis of DNA methylation changes in imprinted genes. The Agilent platform was used for differential methylation analysis of one WBC and LP_LCL pair in order to select regions of several hundred bps with methylation changes, as except for imprinted genes Illumina coverage was limited to two CpG sites for most genes. The Illumina array and pyrosequencing were used to validate differences detected by Agilent in a larger number of LP_LCL pairs.
Our results show that the various technologies we used validate each other in identifying DNA methylation changes. We found random methylation changes in LP_LCLs, FR_LCLs and HP_LCL; the largest frequency was in HP_LCLs. The methylation profiles in FR_LCLs were similar to LP_LCLs, indicating that one cycle of freezing does not induce significant methylation changes.
We also checked DNA methylation patterns at differentially methylated regions of imprinted genes. Imprinted genes are expressed from only one of the parental alleles. There are approximately 60 imprinted genes found in the human genome (http:// www.geneimprint.com). There are a number of single imprinted genes (e.g. DIRAS3, NAP1L5, NNAT) but the majority identified to date are clustered in the genome [10] . The parent-of-origin specific expression of imprinted genes within the cluster is usually regulated by allelic methylation at a single imprinting centre (IC), and often additional differentially methylated regions (DMRs) are present within the cluster, usually within the promoters of the imprinted genes. These parent of origin specific allelic methylation patterns are maintained in somatic cell lineages, with few exceptions [8] . However, it is not known whether this differential allelic methylation is consistently maintained in immortalized LCLs. Our results showed that several imprinted DMRs, but none of the known ICs, have methylation changes. These occur in all type of LCLs, with more changes occurring in HP_LCLs.
Results
We compared DNA methylation between WBCs and LCLs at two levels of resolution: CpG islands and single CpG sites, using two microarray platforms, the Illumina HumanMethylation27 BeadChip and the Agilent CpG island array. For the Agilent array, the methylated DNA immunoprecipitation (MeDIP) was carried out prior to hybridization.
MeDIP is a recently developed technique [11] used to capture methylated DNA sequences. We labeled the immunoprecipitated DNA and input DNA with two different fluorescent dyes and co-hybridized to the Agilent microarrays. Log2 ratios of immunoprecipitated DNA versus input (MeDIP/Input) were used to assess the levels of methylation with higher log2 ratios representing higher levels of methylation. The log2 (MeDIP/Input) is not an absolute methylation value, but can be used to compare methylation levels between samples at the same genomic locations (i.e. microarray probes), but not to compare methylation levels among different genomic locations, as MeDIP enrichment depends on the density of the methylated CpG sites [11, 12] . The Illumina platform utilizes bisulphite converted DNA and thus measures absolute methylation levels at specific CpG sites. The methylation level of each site is measured as C / (C + T) and is represented as a β value ranging continuously from 0 (0% methylated) to 1 (100% methylated).This method provides more accurate methylation level measurements than MeDIP, but less genomic coverage as only one CpG site is measured by each array probe.
We implemented both of the above described techniques in order to study DNA methylation stability in LCLs. We assessed changes in DNA methylation for DNA fragments 500 bp and longer by MeDIP and Agilent CpG island microarray and the DNA methylation changes occurring at specific CpG sites by Illumina methylation platform.
To assess the methylation differences between DNA from WBCs and LCLs, we analyzed methylation profiles for four sets of WBCs, low passage LCLs, and frozen LCLs from two males and two females (WM1/LM1_LP/LM1_FR, WM2/LM2_LP/LM2_FR, WF1/LF1_LP/ LF1_FR, WF2/LF2_LP/LF2_FR) using the Illumina platform, and one pair of WBC and low passage LCL (WM1/LM1_LP) using MeDIP and the Agilent platform (Table 1) . DNA was extracted from the low passage LCLs directly after EBV transformation prior to freezing the cells, and then DNA was extracted a second time after one cycle of freezing (frozen LCLs). Four high passage LCLs (LM3_HP, LF3_HP, LM4_HP, LPID11_HP) had undergone an unknown number of freezing cycles and cell divisions, and were studied using the Illumina array; and two of them (LF3_HP and LPID11_HP) using the Agilent array. As well, one un-paired WBC sample (WF4) was studied with the Agilent array ( Table 1) .
Comparison of genome-wide DNA methylation levels between LCLs and WBCs
DNA methylation across the genome was assessed to determine consistency among WBCs versus LCLs. We first assessed cell type specific differences between WBC and three types of LCLs by performing Manhattan hierarchical clustering analyses of Illumina methylation data. Clustering showed that WBC samples and LCLs cluster in separate groups, whereas there was no clustering of LCLs according to the type (low passage, frozen, high passage) ( Fig. 1 ). This suggests that DNA methylation changes in each group could be either specific for the group or random.
To further assess cell type specific differences, we compared genome-wide DNA methylation profiles between individual samples by calculating correlation coefficients (R) for linear regressions of pair-wise sample comparisons. Sex chromosomes (X and Y) were excluded from these analyses, in order to pick up only cell type specific differences, but not sex specific differences.
Illumina methylation correlations
Correlation coefficients (R) for Illumina methylation are shown in Table 1A . R values among WBC samples ranged from 0.985 to 0.99 (Table 2A) , showing very small inter-individual variation in the DNA methylation of WBCs. However, for pairs of WBCs and LCLs from the same individuals, R values were in range of 0.933-0.947 for WBC/ LP_LCLs and 0.940-0.954 for WBC/FR_LCLs. These results show that methylation profiles in LCLs are not identical to the original WBC samples, either due to the EBV transformation or to the different cell composition, as only B lymphocytes are transformed into LCLs. The correlation is very similar for WBCs/LP_LCLs and WBCs/FR_LCLs pairs, suggesting that one cycle of freezing does not affect genome-wide DNA methylation any more than short term culturing.
We hypothesized that if DNA methylation patterns changed at the same genomic locations in all LCLs, the correlation between LCLs would be very similar to the correlation among WBCs. However, we observed small but significant decreases of correlation coefficients between LP_LCL samples (R = 0.960-0.982, p-value 0.002, paired ttest) and FR_LCL (R = 0.976-0.984, p-value 0.013) compared to WBC samples (R = 0.985-099). Thus, these data indicate that EBV transformation and short-term culture can induce random DNA methylation changes. However one cycle of freezing does not induce increased methylation differences compared to short term culture only.
We further tested DNA methylation in the 4 HP_LCLs that were cultured for a higher number of cell divisions than low passage/frozen cell lines. We did not have matching DNA samples from WBCs for the HP_LCLs and were not able to track how many cell divisions these cell lines had undergone or how many times they were frozen prior to DNA extraction. Correlation coefficients for the pair-wise comparisons of DNA samples from HP_LCLs were in range of 0.905-0.955 (Table 2A ). This is significantly lower than the correlations for WBCs (p-value = 0.0008) and LP_LCLs (p-value = 0.004, un-paired t-test). This reduction in correlation indicates that prolonged cell culturing and repeated freeze-thaw cycles induce progressive random changes in DNA methylation.
Agilent/MeDIP methylation correlations
MeDIP and Agilent CpG island microarray was performed on 5 samples WM1 and LM1_LP, WF4 (WBC DNA from a new-born female) and LF3_HP and LPID11_HP (Table 1) . We performed pair-wise comparisons of all microarray data points in quantile normalized log2 ratios of MeDIP/input. Linear-regression correlation coefficients (R) are shown in Table 2B .
We observed the same trend in this experiment as for the Illumina interrogation. The methylation correlation among two WBC samples run on the Agilent microarray was higher or equal but not lower than correlations between LCL samples. The inter-individual correlation for the WM1_WF4 sample pair run on Agilent was slightly lower (0.972) than for WBC samples (WM1, WM2, WF1, WF2) run on the Illumina microarray (0.985-0.990). This could reflect specific methylation differences of one particular sample WF4, as this sample was collected from a newborn cord blood, whereas the other WBC samples were from adults. 
Detection of known methylation differences using Illumina and Agilent platforms
Known DNA methylation abnormalities in two imprinting centers were used to verify the capability of the Illumina and Agilent platforms to detect methylation changes. We used a DNA sample from a LCL with paternal isodisomy of chromosome 11 in 85-90% of the cells (LPID11_HP). This cell line from a patient with Beckwith-Wiedemann syndrome was known to carry methylation abnormalities at two imprinting centers on chromosome 11p15.5, gain of methylation at the paternal H19 DMR and loss of methylation at the maternal KvDMR [10] . We observed the expected loss of methylation at KvDMR on both the Illumina and Agilent arrays (Figs. 2A and C). The H19 DMR maps 2-4.4 kb upstream of the H19 transcription start site (TSS) (Imprinted Gene Catalogue Records: http://igc.otago.ac.nz). This particular region is not represented on either array, due to the presence of tandem repeats within the H19 DMR [13] . The H19 promoter is also known to be differentially methylated in human WBCs [14] . There are two CpG sites on the Illumina microarray, located between the promoter and the DMR, and as expected gain of methylation was observed at these sites ( Fig. 2B ) in the LPID11_HP sample compared to controls.
Interestingly, the high passage cell line from the healthy individual LM4_HP showed reduced methylation (β value = 0.18) at one of the CpG sites upstream of the H19 transcription start site (genomic location 1977136, build 36), whereas all other samples from WBCs of healthy individuals had β values ranging from 0.4 to 0.46, indicating that methylation at CpG sites within DMRs can be altered in high passage LCLs (Fig. 2B) .
Methylation patterns at imprinted DMRs in LCLs
We analyzed known DMRs involved in the regulation of imprinted gene expression for changes in methylation patterns in LCLs from normal individuals, using both the Illumina and Agilent data. We checked 19 genomic regions that harbor known/potential DMRs [13, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . The coordinates of the DMRs were taken from the Imprinted Gene Catalogue Records (http://igc.otago.ac.nz), when available, or were deduced from published data (Supplementary Table 1 ). The Illumina Infinium methylation array is reported to be accurate for β-value differences ≥0.2 (20%). Therefore this value was chosen as cut off for methylation differences. We set cut off levels of log2 ratio = 0.6 (1.5 fold change in methylation) in at least two contiguous probes for the Agilent data. This methylation difference between WBC and LCL of the same individual was required in order for a methylation change at a DMR to be accepted. For HP_LCL samples, for which we did not have an original WBC sample, the same cut off level was used, but the comparison was between each HP_LCL and all WBC samples run on this platform. Our assumption was that the methylation levels in the WBC samples of healthy individuals, from which HP_LCLs originated, are similar to those in normal WBC samples used in this study (WM1, WF1, WM2, WF2, WF4).
The majority of the DMRs tested retained their methylation patterns in LCLs. Methylation changes meeting the cut offs described above were found in 5 genes. These were DIRAS3, H19, MEG3, MKRN3, NDN and NNAT (Tables 3, Supplementary Table 2 ). The regions with altered methylation detected by microarrays are shown in Figs. 2B, 3, Supplementary Fig. 1 and Supplementary Table 2 . There were more methylation changes occurring in HP_LCLs than in LP_LCLs and Table 2 Correlation coefficients (R) of pair-wise comparisons of all data points (excluding sex chromosomes) between samples run on the Illumina array (A) and Agilent array (B).
WBC samples are highlighted in black, LP_ LCLs are highlighted in white, FR_LCLs are highlighted in light grey, and HP_ LCLs are highlighted in dark grey.
FR_LCLs. The methylation changes found in LCLs from healthy individuals were limited to two CpG sites and included both gains and losses. Gain of methylation was detected at 4 Illumina CpG sites and two Agilent probes for the NNAT promoter in the LPID11_HP sample from a BWS patient. This gain of methylation was detected by both arrays, because it occurred in several consecutive CpG sites ( Supplementary Fig. 1 ).
To see if the DNA methylation changes detected in LCLs by the Illumina platform are limited to single CpG sites from the array, or expanded into surrounding CpGs, we designed pyrosequencing assays targeting the CpG site from the Illumina and several adjacent CpGs, for three genes: DIRAS3, H19, and NNAT. These assays were used to test the samples that were run on the array and additionally one pair of WBC and low passage LCL: WF5 and LF5_LP. DNA methylation values detected by Illumina and pyrosequencing are shown in Fig. 3 . For H19 a CpG site with loss of methylation in LM4_HP from the Illumina array and 4 distal CpGs were tested by pyrosequencing. We found that DNA methylation changes in LM4_HP were limited to only one CpG site from Ilumina array, whereas adjacent CpGs retained normal methylation patterns (Fig. 2B) .
For the DIRAS3 a CpG site (CpG7, Fig. 3D ) with gain of methylation in LF3_HP and LPID11_HP and 6 distal CpG sites were tested by pyrosequencing. Gain of methylation was observed in the CpG7 site and one adjacent CpG in both LF3_HP and LPID11_HP. Additionally, gain of methylation of CpG7 was found in LM5_LP, and loss of methylation was found in CpG1 in LF3_HP (Fig. 3D) .
For NNAT the CpG site with loss of methylation in LM3_HP and gain of methylation in LF2_LP and LF2_FR and two distal CpG sites were validated by pyrosequencing. We observed losses and gains of methylation concordant with array data in all three sites and all three cell lines (Fig. 3F ). Additionally we observed gain of methylation in all three sites in LF3_HP and LPID11_HP, which was also seen in the Illumina array, although slightly smaller than the set cut off of 0.2 methylation difference. We also found that there was gain of methylation for all three sites in LF5_LP compared to its WBC sample.
In summary we found that only a single CpG out of 5 CpGs was susceptible to methylation change for H19, whereas 2 out of 7 and 3 out of 3 CpGs were susceptible to DNA methylation change for DIRAS3 and NNAT respectively. Therefore we conclude the effect of cell culturing can be variable in terms of the length of the affected region.
Differential methylation analyses of Agilent CpG island microarrays
We identified the methylation changes between LM1_LP and WM1 samples first on Agilent microarrays, then checked the methylation patterns in the identified regions on Illumina arrays or by pyrosequencing. We tested additional WBC/LP_LCL pairs in order to verify whether these DNA methylation changes occur in all or just a subset of the LCLs, i.e. are they site-specific or random?
To set the parameters for the detection of methylation changes on the Agilent arrays we used the known methylation differences in samples LPID11_HP and LM1_LP. The LPID11 sample has paternal isodisomy of chromosome 11 in 85-90% of the cells and thus partial loss of methylation (17%) at maternal KvDMR (Fig. 2C) . We adjusted the Partek GS analysis parameters in order to detect the difference in KvDMR methylation in the LPID11 sample (17%) compared to the methylation level in the LM1 sample (52%). These parameters were set to detect a 3-fold (52%/17%) and higher methylation change in 5 or more contiguous probes.
Using these parameters we searched for methylation differences in the LM1_LP sample compared to the WBC sample of the same individual, WM1. We detected 41 altered genomic regions, of which three were hypomethylated and 38 were hypermethylated in LM1_LP compared to WM1 (Table 4) .
To check whether methylation changes found in LM1_LP are random or site-specific we further validated three regions using bisulphite pyrosequencing in 5 pairs of WBCs and LP_LCLs. As well we analyzed 6 regions using the Illumina platform in 4 pairs of WBCs and LP_LCLs.
UNC93B1, HTR1A and hsa-mir-339 (MIR339) were the genes selected for pyrosequencing. Primers for pyrosequencing were designed within the region of the altered DNA methylation, targeting 3 to 5 CpG sites per assay. For each sample, methylation values were averaged for all CpG sites within the assay. Microarray data, together with pyrosequencing results, are shown in Fig. 4A and Supplementary Fig. 2A . As Agilent data do not provide the percentage of methylation, we could not make a direct comparison between the pyrosequencing and Agilent data. However, we observed the same direction of change in methylation on the validation by pyrosequencing. For the UNC93B1 and hsa-mir-339 regions, we observed loss of methylation in all 5 LCLs tested, and for HTR1A we observed gain of methylation in 4 out of 5 LCLs tested.
Probes within 6 genomic regions (FAM84A, HOXA9, DLX5, WT1, HSPA2, IRX5) detected as different in LP1_LP versus WM1 by Agilent arrays were also present on the Illumina array. Therefore Agilent and Ilumina data could be cross-validated. The coordinates of the Illumina CpG sites are shown in Table 4 . All of these regions were found to be hypermethylated in LM1_LP by Agilent. We observed the same direction of methylation change on Illumina in the WM1/LM1_LP sample pair ( Fig. 4B, Supplementary Fig. 2B ). Five of the six gains of methylations found in LM1 did not occur in all 4 LCLs tested by Illumina ( Fig. 4B, Supplementary Fig. 2, right panel) . Thus, these gains of methylation occur in only a subset of LCLs, i.e. these changes in methylation are not site-specific. Only gain of methylation within the WT1 gene was present in all 4 LCLs tested.
Thus the majority of gains of methylation (6 of 7) detected in LCLs represent changes that occur at random genomic locations. To determine the potential shared functionality of the genes acquiring methylation in LM1_LP, we used GO stat ontology analysis to identify the ontology categories which might be significantly overrepresented (p-value b0.01). The overrepresented genes fall into 67 different GO categories, showing that genes with many variable functions demonstrate gain of methylation in LCLs. We also did not observe any pattern in terms of the location of the DNA methylation changes relative to the transcription start of the gene (upstream, downstream, exonic, intronic) ( Table 4 ).
In contrast to gain of methylation, loss of methylation in LM1_LP was detected for only three genes. The methylation status of two of them was confirmed by pyrosequencing in 5 WBCs/LCLs pairs, indicating that loss of DNA methylation in LCLs could be more sitespecific than gain of methylation. Positions of DMRS were either taken from http://igc.otago.ac.nz, or deduced from the cited papers. If parent of origin methylation is unknown in human, it was designated as putative, either based on mouse homology(M) and/or pattern of expression of downstream gene (E). N/A means information is not available due to the lack of the probes on the array. Unkn means unknown, regarding whether the DMR is an imprinting centre (IC). 
Discussion
In this paper, we compared genome-wide methylation profiles of WBC samples, low-passage LCLs pre and post freezing from four individuals and four unrelated high-passage LCLs. Our results show that DNA methylation profiles of LCLs and WBCs of the same individual are not identical (correlation coefficients = 0.933-0.947). It is in agreement with data of Brennan et al. [26] , who studied differences in methylation of 318 genes using Sequenom's MassAR-RAY in 6 pairs of WBCs and LCLs, and found that 8% of these genes showed different methylation in LCLs compared to WBCs. This difference is not surprising, because LCLs originate from B-lymphocytes; the methylation profile for that cell type could be different from the pool of all white blood cells. Additionally EBV-transformation and cell culturing can potentially induce methylation changes. For example, Wilson and Jones [27] found that global methylation levels tend to decrease in fibroblasts over time in culture, whereas immortalized cell lines maintain more stable levels of methylation.
We further looked at the correlation of methylation patterns in LCLs to determine whether alterations occur at specific or random genomic locations. The correlation coefficients were very high between WBC samples (0.985-0.99) indicating very small interindividual variation, but dropped significantly for LCLs pair-wise comparisons, which were especially profound for the cell lines with a history of multiple passages ( Table 2 ). These data indicate that methylation changes occurring in the LCL do not affect all cell lines equally, e.g. a given genomic location can demonstrate altered methylation in one cell line but not in another. Surprisingly, the effect on methylation of one cycle of freezing was no stronger than that of just short term culturing.
We compared the regions with consistent changes in methylation across several probes in one WBC/LCL pair using the Agilent array, followed by validation of several regions using the Illumina array and pyrosequencing. This analysis revealed that the majority of gains of methylation (6 out of 7) detected in LCLs represent changes that do not occur in all WBCs/LCLs pairs and that they affect genes with variable functions. However, loss of methylation was detected in only three genes, and was shown for two of those genes to affect all WBCs/LCLs pairs. We suggest that loss of methylation detected in LCLs compared to WBCs might reflect differences in methylation between B-lymphocytes and other sub-types of WBCs, whereas gain of methylation represents random effects of cell culturing. In support of this, all three hypomethylated genes detected in LCLs by the Agilent platform have known functions in subtypes of white blood cells: UNC93B1 in B-cells [28] , hsa-mir-339 in the human leukemic HL-60 cell line, which originates from peripheral white blood cells [29] , and KLF2 in T-cells [30] . In contrast hypermethylated genes have variable gene functions. For differentially methylated regions associated with imprinted genes, we observed changes in LP_LCLs, FR_LCLs and HP_LCLs in three imprinted genes MKRN3, NDN and NNAT. DIRAS3 and MEG3 were affected in LP_LCLs and HP_LCLs, but not in FR_LCLs, indicating again that one cycle of freezing has less effect on DNA methylation than culturing. H19 was affected in only one HP_LCL line. Interestingly, none of the affected imprinted regions are located within known imprinting centres. MEG3, NDN and MKRN3 harbor secondary DMRs dependent on imprinting centers within bigger imprinting clusters [23, 25] . For single imprinted genes DIRAS3 and NNAT differential methylation levels were observed in somatic tissues [17, 20] ; however, it is unknown if these regions are primary ICs for these genes. The CpG site upstream of the H19 transcription start site showed loss of methylation in the HP_LCL sample. It is located outside of the region defined as the H19 DMR or IC1 of the 11p15.5 imprinted cluster [13] . These data suggest that ICs might be more resistant to methylation change in cell lines than other genomic regions.
The observed changes in LCLs indicate that these cells may not be an optimal screening tool for identification of putative imprinted DMRs by DNA methylation analysis, as DNA methylation levels could shift from the expected 50% due to cell culturing. The expression of imprinted genes could also potentially shift from monoallelic to biallelic due to methylation changes in LCLs or vice versa. As approximately 10% of human genes exhibit random patterns of monoallelic expression within single clones of LCLs [31] , monoallelic expression in LCL could lead to a false conclusion that a gene is monoallelically expressed due to imprinting, when in fact it would be biallelic in a sub-population of these cells.
Overall, DNA methylation analysis in WBCs and three types of LCLs, in imprinted DMRs and genome-wide, showed that two initially very similar methylation patterns can become more and more different as the cell line undergoes multiple cell divisions.
A variety of mechanisms could induce random methylation changes in LCLs. One possibility is a model proposed by Antequera et al. [32] that any gene with an associated CpG island has a significant probability of becoming inactivated by DNA methylation, and if this occurs for a gene essential for survival, the cell will die. Alternatively when the gene is not essential for survival in cell culture, the cell survives carrying the altered methylation pattern, and may even have a selective advantage [32] . This model explains gain of methylation rather than loss and is consistent with our data that demonstrate more frequent random gain of methylation in LCLs.
Another possible reason for non-specific changes in DNA methylation could be clonality of the LCLs. Plagnol et al. examined X inactivation skewing as a measure of clonality in 1174 female LCLs, and found near monoclonality in 20% of the cell lines [33] . Also Simon-Sanchez et al. [1] observed that the ratio of cells with non-germ line heterosomic deletions was reduced in LCLs compared to the original WBC samples, probably due to the putative selective advantage of cells carrying the full diploid genome. The same mechanism could be true for methylation. If the initial population of cells was mosaic for a methylation change in a specific gene, a clonal increase for this specific change could shift the percentage of methylation. If this mechanism is important, the number of non-specific changes should accumulate with increases in cell divisions, which is what we observed.
In summary, we have shown that lymphoblastoid cell lines are prone to DNA methylation changes at random genomic locations especially after a high number of passages. Thus, special care should be taken when identifying disease-associated DNA methylation variants in LCLs. Confirmation of such alterations should be carried out in primary cell types.
Materials and methods

Research subjects
The study was approved by the Research Ethics Board of the Hospital for Sick Children (Toronto). Informed consents were obtained from all individuals.
Lymphoblastoid cell line establishment
Lymphoblastoid cell lines were established in the Biobanking facility, The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, Canada according to standard procedures [34] or purchased from NGIMS Human Genetics Cell Repository, Coriell Institute of Medical Research (Camden, NJ) (http://ccr.coriell.org/).
DNA samples for microarray and pyrosequencing
Four matched sets of white blood cells (WBC) and low passage lymphoblastoid cell lines pre (LP_LCL) and post freezing (FR_LCL) from the same individuals were used in this study for LCL/WBC DNA methylation comparison by microarray. One additional pair of WBC/ LP_LCL was used for pyrosequencing. Four unmatched high passage LCLs (HP_LCL) and one WBC sample were used for microarrays. A cell line with paternal isodisomy for chromosome 11 was used to validate microarray data and to optimize the Agilent microarray analysis parameters. For LP_LCLs cells were cultured after EBV transformation to 4 × 10 7 cells, 4 vials of ∼ 8 × 10 6 cells were frozen and ∼ 5 × 10 6 cells were cultured to 2 × 10 7 cells (which is equivalent to growing up to 16 × 10 7 cells if no freezing is done). For FR_LCLs, 8 × 10 6 cells were thawed and grown up to 2 × 10 7 cells. For HP_LCLs, it was not possible to track the previous history of growth/freezing. DNA was extracted from 2 × 10 7 LCLs and 5 ml of whole blood using phenol-chloroform and ethanol precipitation. Sample information, including cell type, age, sex, source and application used are listed in Table 1 .
MeDIP and Agilent CpG island microarray
Analysis of DNA methylation profiles was performed using methylated DNA immunoprecipitation (MeDIP) followed by Human 244K Agilent CpG island microarray (Agilent, Santa Clara, CA) which contains 237,220 probes, covering 27,800 CpG islands (97.5 % of UCSC annotated CpG islands). The probes are 45-60 bp in length and are spaced at 100 bp from the middle of each probe to the next.
MeDIP was performed as initially described by Weber et al. [11] with slight modifications. Briefly, 10 μg of 5mC antibody (Eurogentec, San Diego CA) was incubated with 50 μl of Dynabeads ® M-28 Sheep anti-mouse IgG (Invitrogen, Burlington, ON) for 5 h in IP buffer (10 mM Na phosphate pH7.0, 140 mM NaCl, 0.05% Triton X-100) at 4°C. Genomic DNA was sonicated to the sizes 200-1000 bp using the Sonicator ® Ultrasonic Liquid Processor, Model XL2000 (Misonix, Farmingdale, NY). 4 μg of DNA was added to the Antibody-beads complex and incubated overnight at 4°C. The DNA-Antibody-Dynabeads complex was washed three times with IP buffer, and incubated in TE pH 8.0, 1% SDS solution with 5 μl of Protein K (10 mg/ ml) for 2 h at 55°C. DNA was further purified using the Qiaquick PCR purification kit (Qiagen, Mississauga, ON).
Immunoprecipitated DNA (21 μl) and 250 ng of sonicated genomic DNA of the corresponding sample of MeDIP DNA was labeled using BioPrime ® Array CGH Genomic Labeling (Invitrogen) Cyanine 3-dCTP and Cyanine 5-dCTP (Perkin Elmer, Waltham, MA) respectively.
Purification of labeled products, array hybridization and scanning were performed at the Microarray facility, The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, Canada according to the Agilent Microarray Analysis of Methylated DNA Immunoprecipitation Manual (Version 1.0, May 2008).
Data from scanned images (tiff) were extracted using Feature extraction software version 9.0 (Agilent), Human Agilent CpG version 20070207 grid file and CGH V4-91 protocol.
Analysis of Agilent CpG island microarray
Agilent microarray data were analyzed using the Partek Genomic Suite (PGS) software according to the algorithm developed by Sadikovic et al. [35] . The feature extraction files were imported into Partek GS as red (Cy5, MeDIP fraction) and green (Cy3, total genomic DNA fraction) processed signals. The data were normalized to baseline, by dividing red signal (MeDIP fraction) by green signal (total genomic DNA fraction), log2 transformed and quantile normalized for all the arrays. Thus, data were represented as log2 (methylated DNA/total DNA) after inter-array normalization for each probe of the array. Higher log2 ratios correspond to higher methylation levels. An ANOVA tool was used to calculate the fold change in methylation for each probe between samples. The Hidden Markov Model (HMM) was applied to the fold change of each probe to identify regions of contiguous probes with similar fold change in methylation. The parameters of HMM were adjusted in order to identify known methylation difference in the LPID11_HP sample at the maternally differentially methylated region KvDMR (11p15.5) compared to the LM1_LP sample. The level of methylation was 17% in LPID11_HP and 52% in LM1_LP sample, according Illumina array data. The following cut-off were used after optimization (min. probes 5, detection states −4.7, 4.7, ignore state 0, max. probability 0.99, genomic decay 10,000, sigma 1) to compare WM1 and LM1_LP samples. These parameters were set to detect approximately 3-fold (51/17) and higher methylation changes in 5 or more contiguous probes.
The detected regions of differences in methylation were annotated using refFlat.txt.gz file (overlap 10, 000 upstream and downstream) downloaded from the UCSC genome browser, and containing the most updated annotation of RefSeq genes. The microarray data were visualized in the UCSC genome browser by creating wig files for each chromosome containing normalized log2 (methylated DNA/total DNA) ratios for each sample.
Illumina's infinium HumanMethylation27 BeadChip
The HumanMethylation27 BeadChip (Illumina, San Diego, CA) contains 27,578 individual CpG sites covering 14,000 genes. Methylation status of the interrogated CpG site is measured as the ratio of signal from a methylated probe (C not converted to T) relative to the sum of both methylated (C not converted to T) and unmethylated probes (C bisulfite-converted to T). 1 μg of genomic DNA was bisulfite converted with Imprint ® DNA Modification Kit according the manufacturer's protocol (Sigma, Oakville, ON). Whole genome amplification, labeling, hybridization and scanning were performed at the Genetic Analysis facility, The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, Canada.
Analysis of Illumina methylation data
The methylation ratios (β value = C/(T+C)) were extracted using the Methylation Module in the Illumina Bead Studio after average normalization. This β value ranges continuously from 0 (unmethylated) to 1 (fully methylated). The correlations among samples and hierarchical clustering were performed in Bead Studio (Illumina). The number of detected probes (p-value b 0.05) was very high for all arrays and varied between 99.3% and 99.9%.
Genome annotation
All genome coordinates used in this paper are according to Build 36 of the human genome annotation.
Bisulfite pyrosequencing
DNA methylation analysis by pyrosequencing were performed as described by Tost and Gut [36] . Pyrosequencing assays containing two PCR primers and one sequencing primer were designed to target 3-7 CpG sites using PSQ Design Software (Biotage, Uppsala, Sweden). One of the PCR primers had a universal tag which annealed to the universal biotinylated primer. Genomic DNA (1 μg) was bisulfite converted with Imprint ® DNA Modification Kit (Sigma) according to the manufacturer's protocol and eluted in 20 μl of water. Bisulfite converted DNA (1 μl) was amplified using Hot-Start Taq-polymerase (Qiagen). Amplicons were analyzed on the Luc 96 pyrosequencer as specified by the manufacturer (Biotage), and % methylation was quantified as a ratio of C (methylated C, not converted to U) to T(not-methylated C converted to U) using Pyro Q-CpG Software (Biotage). The primer sequences are shown in Supplementary Table 3 .
